211 related articles for article (PubMed ID: 33643905)
1. Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China.
Wu Y; Han Y; Yu P; Ouyang Q; Yan M; Wang X; Hu X; Jiang Z; Huang T; Tong Z; Wang S; Yin Y; Li H; Yang R; Yang H; Teng Y; Sun T; Cai L; Li H; Chen X; He J; Liu X; Yang S; Qiao Y; Fan J; Wang J; Xu B
Front Oncol; 2020; 10():599604. PubMed ID: 33643905
[TBL] [Abstract][Full Text] [Related]
2. Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China.
Chen Z; Ouyang Q; Wang Y; Wang J; Wang H; Wu X; Zhang P; Huang J; Zheng Y; Cao W; Shao X; Xie N; Tian C; Liang H; Wang C; Zhang Y; Ren D; Wang X
Front Oncol; 2022; 12():829693. PubMed ID: 35311126
[TBL] [Abstract][Full Text] [Related]
3. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study.
Yuan Y; Zhang S; Yan M; Yin Y; Song Y; Jiang Z
Ann Transl Med; 2021 May; 9(10):831. PubMed ID: 34164465
[TBL] [Abstract][Full Text] [Related]
7. Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation-wide multicenter study.
Guo F; Yi Z; Wang W; Han Y; Yu P; Zhang S; Ouyang Q; Yan M; Wang X; Hu X; Jiang Z; Huang T; Tong Z; Wang S; Yin Y; Li H; Yang R; Yang H; Teng Y; Sun T; Cai L; Li H; Chen X; He J; Liu X; Yang S; Fan J; Qiao Y; Wang J; Xu B
Cancer Med; 2021 Oct; 10(19):6744-6761. PubMed ID: 34472719
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China.
Lei W; Li H; Song G; Zhang R; Ran R; Yan Y; Di L; Jiang H
J Cancer; 2020; 11(22):6612-6622. PubMed ID: 33046982
[No Abstract] [Full Text] [Related]
9. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract][Full Text] [Related]
10. Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer.
Dalal AA; Gauthier G; Gagnon-Sanschagrin P; Burne R; Guérin A; Niravath P; Small T
Adv Ther; 2018 Sep; 35(9):1356-1367. PubMed ID: 30105655
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Steger GG; Egle D; Bartsch R; Pfeiler G; Petru E; Greil R; Helfgott R; Marth C; Öhler L; Hubalek M; Lang A; Tinchon C; Haslbauer F; Redl A; Hock K; Hennebelle M; Mraz B; Gnant M
Breast; 2020 Apr; 50():64-70. PubMed ID: 32062536
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
14. RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use.
Petracci F; Abuin GG; Pini A; Chacón M
Ecancermedicalscience; 2020; 14():1058. PubMed ID: 32582373
[TBL] [Abstract][Full Text] [Related]
15. Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.
Zhao Y; Li Y; Gong C; Xie Y; Zhang J; Wang L; Cao J; Tao Z; Wang B; Hu X
Cancer Med; 2020 Dec; 9(23):8821-8831. PubMed ID: 33022852
[TBL] [Abstract][Full Text] [Related]
16. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
17. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
18. Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options.
Harb WA
Cancer Manag Res; 2015; 7():37-46. PubMed ID: 25653556
[TBL] [Abstract][Full Text] [Related]
19. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.
Royce M; Bachelot T; Villanueva C; Özgüroglu M; Azevedo SJ; Cruz FM; Debled M; Hegg R; Toyama T; Falkson C; Jeong J; Srimuninnimit V; Gradishar WJ; Arce C; Ridolfi A; Lin C; Cardoso F
JAMA Oncol; 2018 Jul; 4(7):977-984. PubMed ID: 29566104
[TBL] [Abstract][Full Text] [Related]
20. Everolimus Plus Letrozole for Treatment of Patients With HR
Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
